Form 4: Calidi Biotherapeutics Director Alan R. Stewart Reports Acquisition of 25,995 Common Stock Shares

Director Alan R. Stewart reports acquiring 25,995 shares of Calidi Biotherapeutics common stock through a grant of restricted stock units.

Summary

• On March 29, 2024, Alan R. Stewart, a director of Calidi Biotherapeutics, Inc., acquired 25,995 shares of common stock.
• The acquisition was a grant of restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan.
• The RSUs fully vested on the grant date and represent a contingent right to receive one share of common stock per RSU.
• Following the transaction, Stewart directly owns 80,650 shares of Calidi Biotherapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The grant of RSUs could be seen as a positive sign of aligning director interests with shareholders, but it's a routine event.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.
• Immediate vesting of the RSUs could incentivize the director to contribute to the company's success.

Industry Context

This filing is a routine disclosure of a director's stock ownership and is typical for publicly traded companies. It reflects compensation practices using equity-based awards.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and restricted stock units to incentivize their directors.
• The size of the grant is likely determined by factors such as the director's role, company performance, and industry benchmarks for director compensation.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning the director's interests with the company's performance.
• Employees may view the equity grant as a positive sign of the company's commitment to its leadership.

Key Dates